Provider review
Wellorithm review: its quiz promises four pounds a week, which is eight times the trial rate
Wellorithm shows no price anywhere. We answered thirty screens of its quiz to find one and never did. What it shows instead, eleven screens in, is a projection: "you'll lose 3.75 to 4.17 pounds per week" and "about 10.1 weeks to reach your goal weight". We gave it a 220-pound starting weight and a 40-pound goal, the same figures we give every seller. STEP 1, the trial nearly every semaglutide claim rests on, averaged 0.48 pounds a week over 68 weeks. This is roughly eight times that rate, quoted to two decimal places, generated from three answers before any clinician has looked at anything.
Partner link — we may earn a commission. How we’re paid
Visit WellorithmOf Wellorithm’s 2 dated product claims documented below, 0 are consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Its quiz projects four pounds a week and a ten-week finish — roughly eight times the rate the landmark trial reported.
Worth trusting if
- You want a thorough contraindication check, which its six health screens genuinely are
Be skeptical if
- You would plan around the weekly rate it projects, which no published trial supports
- You want to know the price before answering thirty screens of questions
- You want to know which pharmacy fills the prescription or which clinician writes it
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Not confirmed
None found
Provenance
Products reviewed at Wellorithm
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection
- Compounded tirzepatide injection
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
2
Products with human evidence
For the advertised use, out of 2 products reviewed here. The evidence concerns the molecule, not Wellorithm's service.
2
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Wellorithm’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)No trial supports this claim
“With medication, you'll lose 3.75 to 4.17 pounds per week. It will take about 10.1 weeks to reach your goal weight of 180. It feels like magic, but it's metabolic science. On average, Wellorithm patients lose over 20% of their body weight. GLP-1 medications are extremely effective — offering you a strong path toward your 40 pound goal weight.”
Read on the Wellorithm site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg. A mean reduction of about 14.9% — for a 220-pound adult that is 32.8 pounds over 68 weeks, an average of 0.48 pounds a week.
Run the numbers Wellorithm gives you against the trial it would have to beat. Its quiz projected 3.75 to 4.17 pounds a week for 10.1 weeks on a 220-pound starting weight — that is 38 to 42 pounds, or 18.2% of body weight, in about ten weeks. STEP 1 reported a mean of 14.9% over 68 weeks, which works out at 0.48 pounds a week. So the projection promises between 7.8 and 8.7 times the trial's weekly rate, and a larger total share of body weight in less than a sixth of the time. The aggregate claim beside it is the same problem stated differently: over 20% on average, for the company's own patients, is above what semaglutide achieved in a controlled trial with monitored adherence, and no source is given. Both figures are visible only inside the quiz, and both are produced from three answers before any clinician has seen anything.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim reaches past the trials
“Looking good! Let's match you with the best medication. Which of these is most important to you? Affordability. Potency. Which formulation options are you interested in?”
Read on the Wellorithm site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly. Its roughly 21% mean at the top dose is the highest published for an approved medicine in this class — and the figure Wellorithm's own-patient average sits level with.
By the time the quiz offers a choice of molecule it has already told you what to expect, and what it told you does not depend on which one you pick. The over-20% average and the four-pounds-a-week projection are shown before the medication question, so they are attached to no particular drug. That matters because the two molecules have materially different published results — about 15% at 68 weeks for semaglutide against about 21% at 72 weeks for tirzepatide at its top dose. A projection that arrives before the choice cannot be true of both, and Wellorithm's is above the better of the two.2
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named, no compounding tier is stated, and no clinician is identified anywhere on their site or across thirty screens of the quiz. Nothing says whether the medication would be made to order under your prescription or dispensed ready-made. The company publishes a telephone number and an aggregate figure — more than 1,200,000 prescriptions written — and nothing about who writes them or who fills them.
Read on the Wellorithm site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
No certificate of analysis, potency, purity or sterility result appears anywhere. What Wellorithm publishes instead is volume and personalization — more than 1,200,000 prescriptions written, over 50,000 success stories, a 4.5 rating on every quiz screen, three testimonial interstitials, and a weekly rate of loss calculated for you personally to two decimal places. None of it is sourced and none of it is dated. The one genuinely careful sentence on the property is on the marketing page rather than in the quiz: when clinically appropriate, these medicines may help address some of the signals involved in hunger and appetite. That is accurate, hedged and attaches no number — and a reader who starts the quiz will never see it again.
Read on the Wellorithm site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Wellorithm publishes no list of states and makes no nationwide claim, on the campaign page or across thirty screens of the quiz. The quiz never asks which state you are in.
Read the full licensing claim
No operating company is named on the pages read, and no clinician is identified. A telephone number is published on the campaign page.
Read on the Wellorithm site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
We did this ourselves
What happens when you sign up with Wellorithm
We went through Wellorithm’s signup ourselves in September 2026: the steps, when a price first appears, and what it asks you for. We stopped at checkout, so nothing here is a prescription or a medical result.
- Starting weight and height
- Goal weight, with "Join over 50K success stories" alongside
- A BMI result — "Perfect! With a BMI of 33.45, we can continue"
- Medication history
- Whether you experience specific symptoms
- A results panel: "On average, Wellorithm patients lose over 20% of their body weight", with a twelve-week chart
- A testimonial interstitial
- A projection: "you'll lose 3.75 to 4.17 pounds per week… about 10.1 weeks to reach your goal weight"
- "We'll move at your pace" — your 40-pound goal is easier than you think
- Sleep quality and hours
- A second testimonial interstitial
- Six separate health and contraindication checklists
- Current weight-loss medication use
- Motivation level
- Medication allergies
- Blood pressure range
- Resting heart rate range
- "Let's match you with the best medication" — affordability or potency
- Current medications
- Formulation preference
- No price appears at any point. Thirty distinct screens in, there is still no dollar figure at all.
- No price appears on their site either, and the FAQ answer about cost describes the category rather than this company.
- A weekly rate of loss and a finish date are shown at screen eleven, before any clinician has reviewed anything.
- That projection is quoted to two decimal places from three answers — a starting weight, a height and a goal.
- An average of over 20% of body weight is claimed for the company's own patients, with no source and no follow-up period.
- Three testimonial interstitials are interleaved with the clinical questions.
- The contraindication screens are genuinely thorough — six of them, covering kidney, liver, gallbladder, cardiac and thyroid history.
Wellorithm support
- Phone
- +1 (877) 402-6778
Assessment
What holds up, and what does not
- Its contraindication screening is thorough — six separate checklists covering kidney, liver, gallbladder, cardiac and thyroid history.
- It asks for blood pressure and resting heart rate, which most signups in this market skip entirely.
- One sentence on its marketing page is properly hedged and attaches no number to the medication.
Show 2 more
- It publishes a telephone number.
- No FDA warning letter.
- Its quiz projects 3.75 to 4.17 pounds a week — around eight times the average rate the landmark trial reported.
- It puts a finish date on that: about ten weeks to lose 40 pounds, against 68 weeks for a smaller share in the trial.
- The projection is quoted to two decimal places from three answers, before any clinician has looked.
Show 6 more
- It claims its own patients average over 20% of body weight lost, with no source and no follow-up period.
- That average is stated beside a twelve-week chart, implying the figure belongs to twelve weeks.
- It shows no price at all — not on the site, and not across thirty screens of its quiz.
- Its own FAQ answer about cost describes the category rather than what it charges.
- No pharmacy, no clinician and no operating company is named.
- "Over 50K success stories" and "1,200,000+ prescriptions written" carry no date or source.
Verdict
The bottom line
Do not plan around the number this quiz gives you. Four pounds a week is roughly eight times what the landmark trial averaged, and the ten-week finish it promises is against a study that ran sixty-eight. If you go ahead anyway, get the price in writing before you start — we answered thirty screens and were never shown one.
Opens Wellorithm's website. A link is not a recommendation to take anything.
Thirty screens, no price
Wellorithm publishes no price on its website. Its own FAQ answer to "How much do these weight loss programs cost?" describes the industry rather than the company and quotes no figure.
So we answered its quiz — thirty distinct screens: goal weight, BMI, motivation, sleep, blood pressure, resting heart rate, medication history, allergies, six separate contraindication checklists, three testimonial interstitials, and a formulation preference.
No dollar figure at any point.
Full analysis — 4 more sectionsWhat it shows you instead · And the average · The sentence that got left behind · What is actually good here
What it shows you instead
Screen eleven, verbatim:
"With medication, you'll lose 3.75 to 4.17 pounds per week. It will take about 10.1 weeks to reach your goal weight of 180."
We gave it 220 pounds and a 180-pound goal — the same figures we give every seller we walk.
Now the comparison:
| Source | Rate | Time | Share of body weight |
|---|---|---|---|
| Wellorithm's projection | 3.75–4.17 lb/week | 10.1 weeks | 18.2% |
| STEP 1 1 | 0.48 lb/week | 68 weeks | 14.9% |
That is 7.8 to 8.7 times the trial's weekly rate — and a larger share of body weight, in under a sixth of the time.
Note the decimals. "3.75 to 4.17" and "10.1 weeks" are precision to the ounce and the day, produced from three answers, before a clinician has seen anything at all.
And the average
Screen seven:
"It feels like magic, but it's metabolic science. Wellorithm GLP-1 Medications — On average, Wellorithm patients lose over 20% of their body weight."
Beside it, a bar chart labeled Week 1 through Week 12.
Over 20% is above what semaglutide achieved in STEP 1 1 and level with what tirzepatide reached at its top dose in SURMOUNT-1 2 — both in controlled trials, over 68 and 72 weeks, with monitored adherence.
This is a claim about a commercial patient population, with no source, no follow-up period, and a twelve-week chart sitting next to it.
The sentence that got left behind
On the marketing page, before the quiz starts:
"When clinically appropriate, GLP‑1 medications may help address some of the signals involved in hunger and appetite."
Hedged. Mechanistic. No number. It is the most accurate sentence Wellorithm publishes, and a reader who clicks through to the quiz will not see it again.
What is actually good here
The screening. Six separate contraindication checklists covering kidney disease, liver disease, gallbladder disease, cardiac history, QT prolongation and thyroid cancer — plus blood pressure and resting heart rate, which most signups in this market never ask about.
That is a real strength, and it makes the projections harder to excuse rather than easier. This is not a company that does not know what careful looks like.
Questions
Frequently asked questions
Will I lose four pounds a week?
Almost certainly not. STEP 1 reported an average of about 15% of body weight over 68 weeks, which for a 220-pound adult works out at roughly half a pound a week. Wellorithm's quiz projects between 3.75 and 4.17 pounds a week, around eight times that rate.
Where does its ten-week estimate come from?
From your height, your weight and your goal — three answers, before any clinician has reviewed anything. It is quoted to one decimal place, which gives an impression of precision the underlying calculation cannot support.
Do its patients really average over 20%?
Wellorithm gives no source, no follow-up period and no sample size for that figure. It sits above what semaglutide achieved in a controlled trial and level with tirzepatide's top-dose result, and it is displayed beside a twelve-week chart.
What does Wellorithm cost?
We don't know, and neither will you before you start. Their site shows no price, its FAQ answer about cost describes the category rather than this company, and we answered thirty screens of its quiz without being shown a figure.
Is anything about it good?
The screening is genuinely thorough — six contraindication checklists plus blood pressure and resting heart rate, which most signups skip. That makes the projections harder to excuse rather than easier, because this is clearly not a company that lacks care when it wants to apply it.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021. Its mean of about 15% is the figure most semaglutide marketing traces back to.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg. Its roughly 21% mean at the top dose is the highest published for an approved medicine in this class.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
Compare
Others selling what Wellorithm sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Wellorithm is on
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Wellorithm's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, mean weight reduction of about 14.9%. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks, roughly 21% mean reduction at the top dose. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.